141 related articles for article (PubMed ID: 29925734)
1. Roles of Glycogen Synthase Kinase-3 (GSK-3) in Cardiac Development and Heart Disease.
Takahashi-Yanaga F
J UOEH; 2018; 40(2):147-156. PubMed ID: 29925734
[TBL] [Abstract][Full Text] [Related]
2. Activator or inhibitor? GSK-3 as a new drug target.
Takahashi-Yanaga F
Biochem Pharmacol; 2013 Jul; 86(2):191-9. PubMed ID: 23643839
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development.
Hardt SE; Sadoshima J
Circ Res; 2002 May; 90(10):1055-63. PubMed ID: 12039794
[TBL] [Abstract][Full Text] [Related]
4. GSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice.
Zhou J; Lal H; Chen X; Shang X; Song J; Li Y; Kerkela R; Doble BW; MacAulay K; DeCaul M; Koch WJ; Farber J; Woodgett J; Gao E; Force T
J Clin Invest; 2010 Jul; 120(7):2280-91. PubMed ID: 20516643
[TBL] [Abstract][Full Text] [Related]
5. Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of Akt-GSK signaling.
Yin H; Chao L; Chao J
Hypertension; 2004 Jan; 43(1):109-16. PubMed ID: 14662648
[TBL] [Abstract][Full Text] [Related]
6. Constitutive glycogen synthase kinase-3alpha/beta activity protects against chronic beta-adrenergic remodelling of the heart.
Webb IG; Nishino Y; Clark JE; Murdoch C; Walker SJ; Makowski MR; Botnar RM; Redwood SR; Shah AM; Marber MS
Cardiovasc Res; 2010 Aug; 87(3):494-503. PubMed ID: 20299330
[TBL] [Abstract][Full Text] [Related]
7. Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation.
Li HJ; Yin H; Yao YY; Shen B; Bader M; Chao L; Chao J
Cardiovasc Res; 2007 Jan; 73(1):130-42. PubMed ID: 17137568
[TBL] [Abstract][Full Text] [Related]
8. Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer.
McCubrey JA; Rakus D; Gizak A; Steelman LS; Abrams SL; Lertpiriyapong K; Fitzgerald TL; Yang LV; Montalto G; Cervello M; Libra M; Nicoletti F; Scalisi A; Torino F; Fenga C; Neri LM; Marmiroli S; Cocco L; Martelli AM
Biochim Biophys Acta; 2016 Dec; 1863(12):2942-2976. PubMed ID: 27612668
[TBL] [Abstract][Full Text] [Related]
9. The signaling interplay of GSK-3β in myocardial disorders.
Sharma AK; Thanikachalam PV; Bhatia S
Drug Discov Today; 2020 Apr; 25(4):633-641. PubMed ID: 32014454
[TBL] [Abstract][Full Text] [Related]
10. Selective loss of glycogen synthase kinase-3α in birds reveals distinct roles for GSK-3 isozymes in tau phosphorylation.
Alon LT; Pietrokovski S; Barkan S; Avrahami L; Kaidanovich-Beilin O; Woodgett JR; Barnea A; Eldar-Finkelman H
FEBS Lett; 2011 Apr; 585(8):1158-62. PubMed ID: 21419127
[TBL] [Abstract][Full Text] [Related]
11. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.
Golpich M; Amini E; Hemmati F; Ibrahim NM; Rahmani B; Mohamed Z; Raymond AA; Dargahi L; Ghasemi R; Ahmadiani A
Pharmacol Res; 2015 Jul; 97():16-26. PubMed ID: 25829335
[TBL] [Abstract][Full Text] [Related]
12. Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure.
Tariq U; Uppulapu SK; Banerjee SK
Curr Drug Targets; 2021; 22(13):1568-1576. PubMed ID: 33655828
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of eukaryotic translation initiation factor 2Bepsilon by glycogen synthase kinase-3beta regulates beta-adrenergic cardiac myocyte hypertrophy.
Hardt SE; Tomita H; Katus HA; Sadoshima J
Circ Res; 2004 Apr; 94(7):926-35. PubMed ID: 15001529
[TBL] [Abstract][Full Text] [Related]
14. Emerging roles of GSK-3α in pathophysiology: Emphasis on cardio-metabolic disorders.
Ahmad F; Woodgett JR
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118616. PubMed ID: 31785335
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of glycogen synthase kinase 3beta during heart failure is protective.
Hirotani S; Zhai P; Tomita H; Galeotti J; Marquez JP; Gao S; Hong C; Yatani A; Avila J; Sadoshima J
Circ Res; 2007 Nov; 101(11):1164-74. PubMed ID: 17901358
[TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinase-3beta plays a pro-apoptotic role in beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes: Role of beta1 integrins.
Menon B; Johnson JN; Ross RS; Singh M; Singh K
J Mol Cell Cardiol; 2007 Mar; 42(3):653-61. PubMed ID: 17292911
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.
Palfi A; Toth A; Hanto K; Deres P; Szabados E; Szereday Z; Kulcsar G; Kalai T; Hideg K; Gallyas F; Sumegi B; Toth K; Halmosi R
J Mol Cell Cardiol; 2006 Jul; 41(1):149-59. PubMed ID: 16716347
[TBL] [Abstract][Full Text] [Related]
18. Role of Glycogen Synthase Kinase-3 in Interferon-γ-Mediated Immune Hepatitis.
Chen CL; Tseng PC; Satria RD; Nguyen TT; Tsai CC; Lin CF
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563060
[TBL] [Abstract][Full Text] [Related]
19. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
Liu SN; Shen ZF
Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
[TBL] [Abstract][Full Text] [Related]
20. The GSK-3 family as therapeutic target for myocardial diseases.
Lal H; Ahmad F; Woodgett J; Force T
Circ Res; 2015 Jan; 116(1):138-49. PubMed ID: 25552693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
